The Safety and Tolerability of CLZ-2002 in Patients With Charcot-Marie Tooth Disease.

A Phase 1, Open-Label, Prospective, Dose-finding Clinical Trial for Evaluation of Safety and Tolerability of Intramuscular Injections of CLZ-2002 for the Treatment of Subjects With Charcot-Marie-Tooth Type 1(CMT 1)

A Phase 1, Open-Label, Prospective, Dose-finding Clinical Trial for Evaluation of Safety and Tolerability of Intramuscular Injections of CLZ-2002 for the Treatment of Subjects with Charcot-Marie-Tooth type 1(CMT 1)

This study is the First In Human (FIH) clinical trial for evaluating the safety and tolerability of IM injections of CLZ-2002 in patients with Charcot-Marie-Tooth disease (CMT) Type 1.

CLZ-2002 is the allogeneic mesenchymal stem cell-derived Neuronal Regeneration Promoting Cells. These cells are Schwann cell-like cells differentiated from tonsillar mesenchymal stem cells. CLZ-2002 helps the remyelination of the damaged peripheral nerves by restoring the myelin sheaths. It also induces the nerve regeneration and myelination pathways in the sciatic nerve and restores abnormal muscle tissues in Charcot-Marie-Tooth disease type 1 (CMT1).

Inclusion Criteria:

• Subjects aged 18 years or older
• Subjects with a proven diagnosis of Charcot-Marie-Tooth disease type 1 at the time of screening visit
• Subjects who have muscle weakness in at least foot dorsiflexion (clinical assessment) at the time of screening visit
• Subjects with a CMT neuropathy score (CMTNS-v2) of 2 or more and 30 or fewer points at the time of screening visit
• Subjects who can understand and are willing to sign a written informed consent document are willing to comply with all study procedures and schedule visits.

Exclusion Criteria:

• Subjects who have any other neuromuscular diseases
• Subjects who have undergone upper and lower limb bone surgery within six months before screening visit
• Subjects who have concerns about muscle strength measurements due to the previous surgery
• Subjects who have severe active infection including severe/purulent cellulitis at the injection sites at screening visit
• Subjects who have a history of hospitalization due to hypersensitivity to antihistamines or allergy or hypersensitivity to certain substances such as food or drugs
• Subjects who have a history of unstable cardiovascular disease defined by the presence of myocardial infarction (STEMI or NSTEMI) within 6 months before the screening or the presence of unstable angina pectoris (in the case of increased frequency of symptoms, increased severity, or signs of prolonged symptoms at moderate activity or rest)
• Subjects who have a history of a transient ischemic attack (TIA) or stroke within 6 months before screening visit
• Subjects who have a positive HIV antibody test, hepatitis B antigen, or hepatitis C antibody test result
• Subjects who have a history of malignant tumors within 5 years before screening visit
• Subjects who have received systemic steroids (inhaled steroids are allowed), immunotherapy, or cytotoxic therapy within 14 days before screening, or who are expected to receive such treatment during the study period
• Subjects who have participated in other clinical trials within 30 days before screening visit
• Pregnant and lactating women or women of childbearing potential and men who plan a pregnancy or are unwilling to use adequate birth control methods& until 30 days after the end of drug administration